

# ISO 5840-3:2013-03 (E)

## Cardiovascular implants - Cardiac valve prostheses - Part 3: Heart valve substitutes implanted by transcatheter techniques

---

<b>Contents</b>		<b>Page</b>
Foreword .....		v
Introduction .....		vi
1	Scope .....	1
2	Normative references .....	1
3	Terms and definitions .....	2
4	Abbreviations .....	10
5	Fundamental requirements .....	10
6	Device description .....	10
6.1	Intended use .....	10
6.2	Design inputs .....	10
6.3	Design outputs .....	13
6.4	Design transfer (manufacturing verification/validation) .....	13
6.5	Risk management .....	14
7	Design verification, testing and analysis/design validation .....	14
7.1	General requirements .....	14
7.2	In vitro assessment .....	14
7.3	Preclinical in vivo evaluation .....	23
7.4	Clinical investigations .....	26
Annex B (informative)	Examples of transcatheter heart valve substitutes, components and delivery systems .....	34
Annex C (normative)	Packaging .....	40
Annex D (normative)	Product labels, instructions for use and training .....	41
Annex E (normative)	Sterilization .....	44
Annex F (informative)	Valve description .....	45
Annex G (informative)	Transcatheter heart valve substitute hazards, associated failure modes and evaluation methods .....	47
Annex H (informative)	In vitro test guidelines for paediatric devices .....	51
Annex I (informative)	Statistical procedures when using performance criteria .....	55
Annex J (informative)	Examples and definitions of some physical and material properties of transcatheter heart valve substitutes and their components .....	56
Annex K (informative)	Examples of standards applicable to testing of materials and components of transcatheter heart valve substitutes .....	69

<b>Annex L (informative) Raw and post-conditioning mechanical properties for support structure materials .....</b>	<b>75</b>
<b>Annex M (informative) Corrosion assessment .....</b>	<b>77</b>
<b>Annex N (informative) Guidelines for verification of hydrodynamic performance .....</b>	<b>80</b>
<b>Annex O (informative) Durability testing .....</b>	<b>84</b>
<b>Annex P (informative) Fatigue assessment .....</b>	<b>86</b>
<b>Annex Q (informative) Preclinical in vivo evaluation .....</b>	<b>92</b>
<b>Annex R (normative) Adverse event classification during clinical investigation .....</b>	<b>95</b>
<b>Annex S (informative) Echocardiographic protocol .....</b>	<b>100</b>
<b>Bibliography .....</b>	<b>103</b>